Efficacy and Safety of Fast-acting Insulin Aspart Compared to NovoRapid® both in Combination with Insulin Degludec with or without Metformin in Adults with Type 2 Diabetes - onset® 9

OVO NORDISK. S.P.A.0 个研究点目标入组 1,091 人开始时间: 2021年6月8日最近更新: 2021年7月12日

研究概览

暂无简介。

•- Male or female, age = 18 years at the time of signing informed consent.
•- Diagnosed with type 2 diabetes = 10 years prior to screening (Visit 1).
•- Treated with a basal-bolus insulin regimen =1 year prior to the day of screening (Visit 1). A basal-bolus insulin regimen is defined as basal insulin once or twice daily and bolus insulin analogue taken with meals at least 3 times daily. Treatment with premixed insulin or soluble insulin combination is not considered a basal-bolus regimen.
•- Treated with or without oral antidiabetic drugs including extended release formulations.
•- HbA1c 7.0 - 10.0% (both inclusive) as assessed by central laboratory at screening (Visit 1).
•Randomisation criterion:
•- HbA1c = 9.0% measured by the central laboratory at Visit 13 (week -1).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 965
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 107

•- Any of the following: myocardial infarction, stroke, hospitalization for unstable angina or transient ischaemic attack within the past 180 days prior to the day of screening (Visit 1).
•- Subjects presently classified as being in New York Heart Association (NYHA) Class IV.
•- Planned coronary, carotid or peripheral artery revascularisation known on the day of screening (Visit 1).
•- Treatment with injectable GLP-1 receptor agonists in a period of 90 days prior to screening (Visit 1).
•- Anticipated initiation or change in concomitant medications (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or corticosteroids).

发起方

OVO NORDISK. S.P.A.